Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

NCT05182164 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT05182164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05182164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Lead sponsor
Institut Bergonié
Phase
Phase 2
Overall status
Recruiting
Start date
April 25, 2022
Completion date
December 31, 2027
Enrollment
119 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced soft-tissue sarcoma, ewing sarcoma, osteosarcoma, soft tissue sarcoma adult, undifferentiated pleomorphic sarcoma